Dr Huw Jones, CEO of Chronos Therapeutics Ltd, been awarded Best CEO, 2016. He is one of six finalists nominated anonymously for the European Drug Discovery Industry award last year.
“We are developing a re-purposed asset for the devastating disease ALS and actively searching for more discoveries in neurodegeneration,” Jones said.
“This award recognises Chronos’ team effort in developing and acquiring treatments for patients with degenerative and behavioural diseases.”
Chronos Therapeutics is a privately held biotechnology company focused on diseases of ageing, brain and nervous system disorders. Chronos has a laboratory in Oxford that screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen.
It has a library of re-purposed molecules showing promise for brain and neurological diseases. The lead compound, RDC5, is being developed for the fatal neurodegenerative disease, Amyotrophic Lateral Sclerosis (ALS).
Chronos recently acquired three new chemical entity (NCE) development programs for CNS diseases. The most advanced programme is initially targeting fatigue associated with multiple sclerosis, with the others addressing behavioural and neurodegenerative conditions.
